Qilu Hospital of Shandong University
Jinan, Shandong, 250100, China
Location status: Recruiting
Location contact
Wei Zhao
PRINCIPAL_INVESTIGATOR
Yuguo Chen
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07232758
This study mainly evaluated the safety and tolerability, as well as the pharmacokinetic characteristics, of the injectable drug HRS-2183 after single and multiple administrations in healthy subjects.
Interested in participating?
Request Info18 year–45 year
All sexes
Interventional
Phase 1
Jinan, Shandong, 250100, China
Location status: Recruiting
Wei Zhao
PRINCIPAL_INVESTIGATOR
Yuguo Chen
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
HRS-2183
placebo
Time frame: Evaluation was performed up to the seventh day / the 16th day
Time frame: Evaluation was performed up to the third day
Time frame: Evaluation was performed up to the third day
Time frame: Evaluation was performed up to the third day
Time frame: Evaluation was performed up to the third day
Time frame: Evaluation was performed up to the third day
Time frame: Evaluation was performed up to the third day
Time frame: Evaluation was performed up to the third day
Time frame: Evaluation was performed up to the third day
Time frame: Evaluation was performed up to the third day
Time frame: Evaluation was performed up to the third day
Time frame: Evaluation was performed up to the 12th day
Time frame: Evaluation was performed up to the 12th day
Time frame: Evaluation was performed up to the 12th day
Time frame: Evaluation was performed up to the 12th day
Time frame: Evaluation was performed up to the 12th day
Time frame: Evaluation was performed up to the 12th day
Time frame: Evaluation was performed up to the 12th day
Time frame: Evaluation was performed up to the 12th day
Time frame: Evaluation was performed up to the 12th day
Time frame: Evaluation was performed up to the 12th day
Time frame: Evaluation was performed up to the 12th day
Time frame: Evaluation was performed up to the 12th day
Contact information is provided by the study sponsor or research team.
Jiangsu HengRui Medicine Co., Ltd.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.